AN2 Therapeutics (NASDAQ: ANTX) awards 20,400 stock options to director

Rhea-AI Filing Summary

AN2 Therapeutics director Margaret M. FitzPatrick received a grant of stock options for 20,400 shares of AN2 Therapeutics, Inc. common stock. The options carry an exercise price of $0.00 per share and are reported as a direct derivative holding.

The option shares are scheduled to vest on February 20, 2027, provided FitzPatrick continues to provide service to the company through that date. After this award, she holds a total of 20,400 stock options according to the filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FitzPatrick Margaret M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,400	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 20,400 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FitzPatrick Margaret M

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.04	02/20/2026		A		20,400		(1)	02/19/2036	Common Stock	20,400	$0	20,400	D

Explanation of Responses:

1. The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.

	/s/ Lucy Day, Attorney-in-Fact for Margaret M. FitzPatrick	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AN2 Therapeutics (ANTX) disclose about Margaret M. FitzPatrick in this Form 4?

AN2 Therapeutics disclosed that director Margaret M. FitzPatrick received a grant of stock options for 20,400 shares. These are derivative securities with an exercise price of $0.00 per share and are reported as directly owned following the transaction.

How many AN2 Therapeutics (ANTX) stock options were granted to Margaret M. FitzPatrick?

The filing shows a grant of 20,400 stock options to Margaret M. FitzPatrick. These options are classified as a derivative security and represent rights to buy AN2 Therapeutics common stock, subject to the vesting conditions described in the footnotes.

What are the vesting conditions on Margaret M. FitzPatrick’s AN2 Therapeutics stock options?

The option shares vest on February 20, 2027, if Margaret M. FitzPatrick provides continuous service to AN2 Therapeutics through that date. If this service condition is not satisfied, some or all of the option grant may not vest as scheduled.

What is the exercise price of the stock options granted to the AN2 Therapeutics director?

The stock options granted to director Margaret M. FitzPatrick have an exercise price of $0.00 per share. This means she is not required to pay cash per share upon exercise, according to the terms reported in the Form 4 filing.

How many AN2 Therapeutics options does Margaret M. FitzPatrick hold after this Form 4 transaction?

After the reported transaction, Margaret M. FitzPatrick beneficially owns 20,400 stock options in AN2 Therapeutics. The Form 4 indicates that this total reflects her direct derivative holdings following the grant on February 20, 2026.